ARVINAS INC. - COMMON STOCK

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

24 أبريل 2024 16:30:38 بحسب Nasdaq GlobeNewswire

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

11 أبريل 2024 07:00:49 بحسب Nasdaq GlobeNewswire

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

18 مارس 2024 16:40:46 بحسب Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 مارس 2024 07:00:04 بحسب Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27 فبراير 2024 07:00:07 بحسب Nasdaq GlobeNewswire

Arvinas Announces Chief Financial Officer Transition

20 فبراير 2024 16:05:04 بحسب Nasdaq GlobeNewswire

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

20 فبراير 2024 07:00:44 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

06 فبراير 2024 06:45:00 بحسب Nasdaq GlobeNewswire

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

01 فبراير 2024 16:30:20 بحسب Nasdaq GlobeNewswire

Arvinas Appoints Jared Freedberg as General Counsel

16 يناير 2024 17:01:06 بحسب Nasdaq GlobeNewswire

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

05 ديسمبر 2023 22:52:59 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

05 ديسمبر 2023 13:33:42 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

28 نوفمبر 2023 17:05:13 بحسب Nasdaq GlobeNewswire

Arvinas Announces Oversubscribed $350 Million Private Placement

27 نوفمبر 2023 07:00:10 بحسب Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 نوفمبر 2023 07:00:34 بحسب Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

02 نوفمبر 2023 07:00:59 بحسب Nasdaq GlobeNewswire

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

22 أكتوبر 2023 07:00:58 بحسب Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day

18 أكتوبر 2023 07:00:27 بحسب Nasdaq GlobeNewswire

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

15 أكتوبر 2023 18:07:41 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

15 أكتوبر 2023 18:05:45 بحسب Nasdaq GlobeNewswire